Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes

被引:0
作者
John W Baddley
Jennifer M Stephens
Xiang Ji
Xin Gao
Haran T Schlamm
Miriam Tarallo
机构
[1] University of Alabama at Birmingham,Department of Medicine, Division of Infectious Diseases
[2] Pharmerit North America LLC,undefined
[3] Pfizer Inc,undefined
[4] Pfizer Inc,undefined
来源
BMC Infectious Diseases | / 13卷
关键词
Aspergillosis; Voriconazole; Fluconazole; ICU; Length of stay; Hospital costs;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 124 条
[1]  
Segal BH(2009)Aspergillosis N Engl J Med 360 1870-1884
[2]  
Lin SJ(2001)Aspergillosis case-fatality rate: systematic review of the literature Clin Infect Dis 32 358-366
[3]  
Schranz J(2002)Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 408-415
[4]  
Teutsch SM(2007)Invasive aspergillosis in the intensive care unit Clin Infect Dis 45 205-216
[5]  
Herbrecht R(2004)Invasive aspergillosis in critically ill patients without malignancy Am J Respir Crit Care Med 170 621-625
[6]  
Denning DW(2007)Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients Intensive Care Med 33 1694-1703
[7]  
Patterson TF(1997)The challenge of invasive aspergillosis: increasing numbers in diverse patient groups Int J Infect Dis 2 61-63
[8]  
Bennett JE(2008)Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients Am J Respir Crit Care Med 177 27-34
[9]  
Greene RE(2009)Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients Am J Health Syst Pharm 66 1711-1717
[10]  
Oestmann JW(2004)Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence J Hosp Infect 56 269-276